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Recap of Influenza Session, June 2019
 Influenza surveillance and vaccine effectiveness updates
 Overview of 2018-19 influenza vaccine safety surveillance
 Proposed recommendations for the 2019-20 influenza season
Work Group Activities and Discussion Since June 2019
 2019-20 ACIP Influenza Statement Published August 23, 2019
 Series of discussions to develop protocol for systematic review of influenza 
vaccines for older adults
–
–
Selection of relevant comparisons and outcomes
 Presentation of Phase 3 trial data for quadrivalent high-dose inactivated 
influenza vaccine for persons 65 years of age and over
Fluzone High-Dose (trivalent high-dose inactivated influenza vaccine) 
licensed for this population since 2009)
Agenda Overview
 U.S. Influenza Activity Update
–
–
–
Ms. Lynnette Brammer, CDC/NCIRD
 QIV-HD Clinical Development and Phase 3 Safety and Immunogenicity 
Study Results
Dr. Lee-Jah Chang, Sanofi Pasteur
 Summary and Work Group Considerations
Dr. Lisa Grohskopf, CDC/NCIRD
